Under construction – not a live service
Sign in
Taking people in SenegalNo phase

Observational study of treatment for children with Burkitt lymphoma

Studies children with Burkitt lymphoma, a blood cancer, and how they respond to treatment.

Key facts

Who runs it
French Africa Pediatric Oncology Group
Where
Dakar, SenegalSee the siteAlso in 5 other countries, 6 sites
Trial code
Registry title
Recommendations for the Treatment of Children With Burkitt's Lymphoma
Status
Recruiting
People taking part
1,000 people, planned
Started
1 Nov 2020
Expected to end
31 Dec 2030
Type of study
Observational
Treatments tested
  • OBSERVATIONAL
Record updated
2 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children with Burkitt's lymphoma, a fast-growing cancer of the B cells, in any part of the body.

Age
Up to 18 years
Sex
All sexes can join.
Disease stage
Burkitt's lymphoma in any location, confirmed by cytology or histology.
Earlier treatment
The child must not have been treated before.
Biomarker or test result
The tumour must be a B cell tumour.

Main reasons for not taking part

  • Tumour that is not a B cell tumour
  • Child has been treated before
  • Another illness that makes the treatment unsuitable
  • Parents refuse

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Clinical diagnosis of Burkitt's Lymphoma: all location. Diagnosis by cytology or histology. Not possible to follow all the treatment
  • -

Who cannot take part

  • Not a B Cell tumor. Child has been previously treated. Child has also another illness which would render the treatment incompatible. Parents refusal

Where in Senegal

Also in 5 other countries, 6 sites

  • Hôpital Aristide Le DantecDakar, SenegalContact: Fatou-Binetou DIAGNE AKONDE, DrTaking people

About the trial

What the trial wants to find out

This is the 4th LMB study by the French African Pediatric Oncology Group (GFAOP). The study hopes to be able to evaluate children earlier with stage I and II disease and to evaluate treatment response earlier so that the units can decide if a change in treatment is necessary, it is also hoped to provide an intensification of treatment for the stage IV disease.

The group in the trial

  • All children with Burkitt lymphoma and in 2 units the addition of Rituximab

    An amendment has been added to give 4 injections during induction treatments as in the study in adults, that is to say 1 injection on D1 and D6 of each induction treatment, COPM or COPADM depending on the risk group in two centers. It is an amendment of the therapeutic recommendations "GFA LMB2019" which are the basis, the other centers will continue with this GFALMB2019 protocol as is

    Treatment: OBSERVATIONAL

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Recommendations for the Treatment of Children With Burkitt's Lymphoma
Plain-language title
Observational study of treatment for children with Burkitt lymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
2 March 2026